Page 8 - Thomas Gidoin News Today : Breaking News, Live Updates & Top Stories | Vimarsana
GenSight Biologics Appoints Country Leads for France, Germany and the UK in Preparations for LUMEVOQ® Commercial Launch
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
GenSight Biologics Appoints Françoise de Craecker to its Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
GenSight Biologics Appoints Françoise de Craecker to its Board of Directors
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
GenSight Biologics Announces Publication of Results from the REALITY LHON Natural History Study in the Journal Eye
May 3, 2021 GMT
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
PARIS (BUSINESS WIRE) May 3, 2021
Regulatory News:
Figure 1. Evolution of BCVA in ND4-LHON patients aged ≥ 15 at onset of vision loss (Graphic: Business Wire)
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that
GenSight Biologics Announces the Filing of its 2020 Universal Registration Document
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2020 Universal Registration Document (URD) in English with the French market authority (
Autorités des Marchés Financiers, or AMF) under the reference D.21-0276.
The universal registration document notably includes:
the 2020 annual financial report;
the management report;
the description of the share buyback program.
This universal registration document may be consulted on the Company s website (www.gensight-biologics.com), Investors section, and on the AMF s website (www.amf-france.org).